Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DatumZeitQuelleÜberschriftSymbolFirma
22/01/202513h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
14/01/202522h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
10/01/202521h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
26/12/202415h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
26/12/202415h48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/12/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
19/12/202414h01GlobeNewswire Inc.Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
10/12/202401h35GlobeNewswire Inc.CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
02/12/202421h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
14/11/202414h46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEGNLegend Biotech Corporation
12/11/202413h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
12/11/202413h00GlobeNewswire Inc.Legend Biotech Reports Third Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
07/11/202413h30GlobeNewswire Inc.Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LEGNLegend Biotech Corporation
05/11/202415h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
05/11/202415h10GlobeNewswire Inc.Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
04/11/202413h30GlobeNewswire Inc.Legend Biotech Appoints Alan Bash as President of CARVYKTI®NASDAQ:LEGNLegend Biotech Corporation
24/10/202414h00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Third Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
22/10/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
21/10/202422h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
15/10/202413h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
03/10/202413h30GlobeNewswire Inc.Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in PhiladelphiaNASDAQ:LEGNLegend Biotech Corporation
27/09/202422h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
27/09/202422h35GlobeNewswire Inc.CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second LineNASDAQ:LEGNLegend Biotech Corporation
25/09/202421h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202422h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202416h46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202414h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
27/08/202413h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
20/08/202414h00GlobeNewswire Inc.Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
09/08/202413h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN

Kürzlich von Ihnen besucht

Delayed Upgrade Clock